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Summary 
Ligands targeting G protein-coupled receptors (GPCRs) are currently classified as either orthosteric, 
allosteric or dualsteric/bitopic. Here, we report a new pharmacological concept for GPCR functional 
modulation: sequentially activating ligands. A hallmark feature of these is the initial contact with and 
transient activation of a first receptor site followed by sustained activation of a second 
topographically distinct site. We identify 4-CMTB, previously classified as a pure allosteric agonist of 
the free fatty acid receptor FFA2, as the first sequential activator and corroborate its two step 
activation in living cells by tracking integrated responses with innovative optical- and impedance-
based label-free biosensors capable of visualizing multiple signaling inputs in real-time. We validate 
this unique pharmacology with traditional cellular readouts along with mutational and 
pharmacological perturbations including computational techniques, and propose a kinetic model 
applicable to analysis of sequential receptor activation. Our proof-of-concept study unveils 4-CMTB 
as the prototype ligand epitomizing a heretofore-unobserved molecular mechanism of receptor 
activation.  
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Introduction 
GPCRs are involved in virtually every (patho)physiological process in mammals and therefore have 
been the most successful targets for drug development1,2. Most drugs are assumed to act via binding 
to the orthosteric site, thereby competing with the endogenous ligands that naturally regulate 
receptor function. During the past years allosteric modulation of GPCRs has received considerable 
interest, and significantly allosteric ligands (that is ligands that bind to a distinct location) are 
emerging as promising alternatives for therapeutic intervention because they may obviate several of 
the inherent challenges of orthosteric target-centered approaches3–6. First, allosteric ligands may 
achieve greater receptor subtype selectivity because allosteric epitopes are less well conserved than 
orthosteric recognition sites. Second, allosteric ligands show the advantage of “use-dependence”, 
which entail lower propensity for receptor desensitization7 and may also provide a means to fine-
tune cellular signaling by favoring selected signaling routes over others8. Third, allosteric modulators 
are characterized by their saturability of effect on the orthosteric recognition site. This in turn allows 
preservation of a low-level tone of the endogenous ligand and thus safeguards physiological function 
even under conditions of full occupancy of the allosteric site4,6. 
To date, allosteric ligands are classified as inhibitors (negative allosteric modulators, NAMs), 
potentiators (positive allosteric modulators, PAMs) or allosteric agonists, as well as silent or neutral 
allosteric modulators (SAMs/NALs)6,9,10. Recently, dualsteric or bitopic ligands have become available 
as an additional class of pharmacological agents for modulating GPCR function11,12. These ligands 
harbor two pharmacophores connected by a linker to concomitantly engage both orthosteric and 
allosteric receptor binding pockets. Thus, dualsteric/bitopic ligands combine receptor subtype 
selectivity with the capacity to fine-tune the receptor’s natural signaling pattern13,14 (Bock 
NatComm).  
 This study introduces a novel mechanism of pharmacological intervention by bifunctional ligands to 
unlock a temporal dimension of GPCR modulation that is inaccessible by the conventional 
5 
 
understanding of orthosteric, allosteric and dualsteric/bitopic ligands: Sequential receptor activation. 
This mechanism is posited to explain the differences observed in investigations into the molecular 
modes of action of two agonists for the free fatty acid receptor 2 (FFA2, formerly GPR43)15,16: the 
short chain fatty acid propionic acid C3 and the small molecule 4-CMTB (2-(4-chlorophenyl)-3-
methyl-N-(thiazol-2-yl)butanamide). Propionic acid is an endogenous agonist targeting the 
orthosteric pocket of FFA215,16. 4-CMTB is a synthetic ligand that was identified in a high-throughput 
screening campaign in an effort to achieve selective activation of FFA2 over the closely related FFA3 
receptor17. Interestingly, considerable optimization efforts have failed to provide ligands with 
significantly higher potency than the initial hit and attempts to map its binding site have been 
inconclusive18,19. Nevertheless, of the studies undertaken with 4-CMTB to date, all are indicative of a 
purely allosteric mode of action17–22. 
Herein, we confirm allosteric receptor engagement of FFA2 by 4-CMTB but additionally reveal a 
hitherto unappreciated orthosteric component in its mechanism of action. Intriguingly, this 
orthosteric activation is only temporary in nature but is followed by sustained activation via the 
allosteric site. We validate this stepwise mode of receptor activation using a broad array of signaling 
measurements under kinetic and equilibrium conditions in combination with pharmacological 
perturbations, receptor mutagenesis and structural analysis. We also develop a kinetic model 
applicable to the analysis of sequential receptor activation. 
With the identification of 4-CMTB as bifunctional ortho-allosteric agonist we not only expand/enrich 
the pharmacological toolbox of GPCR modulators/enrich current pharmacological concepts but 
moreover add a new dimension to the repertoire of cellular communication via GPCRs in space and 
time.  
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Results 
Label-free techniques unveil different activation modes of C3 versus 4-CMTB 
Label-free assays based on the detection of dynamic mass redistribution (DMR) or bioimpedance 
capture integrated responses in living cells with high temporal resolution and broad signaling 
pathway coverage23–26. They have proven particularly well suited to visualize cellular activation 
profiles of signaling-competent proteins such as GPCRs27–29. We initially set out to compare the 
cellular reaction to either the endogenous, orthosteric agonist propionic acid (C3) or the synthetic 
allosteric agonist 4-CMTB in HEK293 cells engineered to stably express the human FFA2 wild-type 
receptor (hFFA2, hFFA2-wt). Label-free impedance sensing unraveled a striking temporal difference 
in the signaling patterns triggered by the two receptor ligands. C3 provoked a sharp transient 
negative peak rapidly after compound addition that reversed quickly toward baseline and that was 
followed by a second gradually descending phase. 4-CMTB largely lacked the first spike but preserved 
the second phase signal (Figure 1A,B, for magnification of the early timescale see Figure S1A,B). 
Comparable results were obtained in optical biosensor-based DMR recordings. C3 generated a 
uniform signature with a maximal DMR peak at about 1,500 sec, after which it decayed slowly (Figure 
1C). 4-CMTB, in contrast, evoked a less pronounced initial increase with a delayed maximal response 
at approx. 3,000 sec. Yet, overall DMR profiles at later time points were comparable to those 
generated by C3 (Figure 1D). To consider these temporal differences, we quantified concentration-
effect relationships for both ligands at early and late time points. This analysis revealed partial 
agonism of 4-CMTB for the first signaling impulse (Figure 1E,F), but full agonism at later time points 
(Figure 1G,H, and Table S1). All cell responses in the label-free readouts were specifically mediated 
via the hFFA2 receptor, since untransfected cells did not react upon compound addition (Figure 
S1C,D).  
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Structural integrity of the orthosteric site impacts on 4-CMTB signaling dynamics 
A key residue within the orthosteric binding pocket of hFFA2 is R2557.35 in helix 7 (Ballesteros-
Weinstein indexing system in superscript), which - if mutated to alanine (hFFA2-R255A) - renders 
hFFA2 unresponsive to short chain fatty acids despite appropriate surface expression17 (30, see 
methods). Consistent with these findings, C3 was completely inactive on the hFFA2-R255A mutant 
receptor in both impedance- and optical-based label-free whole cell recordings (Figure S1E,F). As 
expected, 4-CMTB retained the capacity to trigger cell activation via the hFFA2-R255A receptor, 
corroborating its non-orthosteric mode of action. However, we noted that the kinetic profile of 
4-CMTB differed significantly from that obtained at the wild-type receptor. Both label-free assays 
yielded temporal fingerprints for 4-CMTB indicative of impaired early but enhanced late cell 
responses (Figure 1I,J; for time-dependent quantification of label-free signatures at the hFFA2-R255A 
receptor see Figure 1K,L). Our mutagenic approach indicates that lack of orthosteric R2557.35 impacts 
on signaling by 4-CMTB, either because signaling via the allosteric site requires the integrity of the 
orthosteric site and/or because 4-CMTB also interacts directly with the orthosteric receptor site.  
CATPB serves as a selective orthosteric probe  
To provide a complementary view on the biological role of the orthosteric binding site for 4-CMTB 
signaling, we also manipulated hFFA2 function using traditional pharmacological perturbation with 
CATPB, a small molecule previously reported to competitively antagonize hFFA2-wt receptor 
function21 (Figure 2A). We initially verified competitive antagonism of CATPB with C3 using Schild 
analysis of DMR recordings at the hFFA2-wt receptor (pA2: 7.61 ± 0.04, slope: 0.96 ± 0.01) (Figure 
2B,C). Competitive inhibition of C3 function by CATPB was further substantiated in ERK1/2 
phosphorylation assays (Figure S2A,B). In contrast, at no time did CATPB affect non-orthosteric 4-
CMTB-mediated activation of the hFFA2-R255A mutant in label-free recordings (Figure 2D,E; for 
quantification of CATPB effects at early and late time points see Figure 2F). These data suggest 
occupancy of non-overlapping binding sites by CATPB and 4-CMTB at equilibrium and unambiguously 
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define CATPB as an orthosteric probe, competing with C3 for a common site within the orthosteric 
hFFA2 pocket. 
Attenuation of orthosteric signaling by CATPB remodels the dynamics of 4-CMTB-mediated FFA2 
activation 
In accordance with an orthosteric mode of action, high concentrations of CATPB completely blocked 
C3-induced cell response in label-free assays (Figure 3A, Figure S3A). In contrast, saturating 
concentrations of CATPB exclusively blunted the first, but preserved or even enhanced the second 
signaling wave mediated by 4-CMTB (Figure 3B, Figure S3B, for quantification of early and late 
responses in label-free DMR and impedance assays, respectively, see Figure S3C,D). CATPB did not 
affect DMR or impedance responses triggered by endogenously expressed P2Y receptors, confirming 
the specific nature of hFFA2-wt receptor inhibition (Figure S3E,F).   
To elucidate whether the characteristic temporal inhibition pattern of CATPB on 4-CMTB-induced cell 
responses is echoed in traditional GPCR signaling readouts, multiple parallel assays were employed 
that either capture rapid (mobilization of intracellular Ca2+), delayed (accumulation of IP as well as 
inhibition of forskolin-mediated cAMP production) or both cell responses (ERK1/2 phosphorylation 
assays). Indeed, the transient rise of Ca2+, which is detectable within seconds after addition of both 
C3 and 4-CMTB, is attenuated by CATPB (Figure 3C,D). For both ligands, inhibition was complete and 
entirely consistent with competitive antagonism (Figure 3E, Table S2). Second messenger production 
in IP (Figure 3F) and cAMP accumulation assays (Figure 3G) after 4-CMTB stimulation was insensitive 
to inhibition with CATPB. This is in contrast to complete inhibition that was apparent when C3 was 
employed as the activating stimulus. Inhibition of early, partial inhibition of intermediate, but lack of 
CATPB sensitivity at late signaling time points is also recapitulated in ERK1/2 phosphorylation assays 
examining the time-dependence of interaction between 4-CMTB and CATPB (Figure 3H; see Figure 
S3G for unperturbed 4-CMTB pERK1/2 kinetics over time). Inhibition of pERK1/2 levels by CATPB was 
FFA2 receptor-dependent, since serum-induced controls were unaffected by the antagonist (Figure 
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S3H). In summary, as with real-time label-free data, second messenger assays provide strong support 
for the notion that 4-CMTB mediates early cellular responses via transient activation of the 
orthosteric site. 
Mutational analysis unveils dual input control of 4-CMTB signaling at the wild-type receptor 
A corollary of orthosteric receptor activation by 4-CMTB is selective abrogation of early, but not late, 
cell responses in mutant forms of hFFA2 lacking a functional orthosteric site. To test this prediction, 
we investigated the temporal signaling pattern of 4-CMTB at the hFFA2-R255A receptor in both Ca2+ 
and second messenger assays. Consistent with our prediction, rapid signaling of transient Ca2+ flux 
upon 4-CMTB stimulation was abolished (Figure 3I) but delayed cell responses in second messenger 
(Figure 3J,K) and ERK1/2 accumulation assays (Figure 3L) were preserved. Thus, we posit that 
4-CMTB dually controls input at the wild-type receptor by sequentially activating the orthosteric 
followed by the allosteric site, respectively. 
An ECL2 swap mutant exaggerates the transient orthosteric action of 4-CMTB 
We next chose to investigate the mechanism of receptor activation by 4-CMTB using a chimeric 
hFFA2 receptor, in which the extracellular loop 2 (ECL2) of hFFA2 was exchanged for the counterpart 
of the cognate hFFA3 receptor (hereafter hFFA2-ECL). This mutant was designed previously in an 
effort to understand transmission of allosteric effects by 4-CMTB19. Both C3 and 4-CMTB displayed 
temporal activation patterns in hFFA2-ECL expressing HEK293 cells that were comparable with those 
observed at the wild-type receptor (Figure S4A-D, compare with Figure 1C,D,F,H)). Inhibition of C3 by 
CATPB remained competitive at the hFFA2-ECL receptor (pA2: 7.00 ± 0.10; slope: 1.01 ± 0.04; Figure 
S4E,F). Consistent with this, saturating concentrations of CATPB completely inhibited C3-induced 
DMR responses at all times (Figure 4A). Intriguingly, CATPB inhibition of 4-CMTB signaling differed 
significantly from the pattern observed for the wild-type receptor because both initial and delayed 
activation of 4-CMTB was largely diminished (Figure 4B, compare with Figure 3B). When we 
compared CATPB modulation of C3 and 4-CMTB signaling at early time points at the hFFA2-ECL 
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receptor, we observed complete inhibition indistinguishable from competitive antagonism (Figure 
4C,D) and reminiscent of the profile at the wild-type receptor (Figure 4E,F). Quantitative analysis of 
CATPB IC50-shifts indicates competitive antagonism for both C3 and 4-CMTB and thus strengthens the 
conclusion of temporary orthosteric receptor activation by 4-CMTB (Figure 4G,H, Table S3). 
Moreover, CATPB remained able to partially inhibit delayed 4-CMTB-induced cell responses at the 
hFFA2-ECL mutant (Figure S4G,H), whereas it gradually turned into enhancement over time at the 
wild-type receptor (Figure S4I,J; compare G with I, and H with J; for snap-shot quantification of time-
dependent modulation by CATPB of 30 µM 4-CMTB see Figure 4I). These data argue for a gatekeeper 
role of ECL2 in determining the duration of orthosteric first phase agonism by 4-CMTB. To challenge 
this hypothesis, we introduced the Arg255Ala mutation into the hFFA2-ECL receptor resulting in the 
double mutant hFFA2-R255A-ECL. DMR recordings in hFFA2-R255A-ECL expressing cells mirror the 
traces obtained in hFFA2-ECL cells in the presence of CATPB: loss of the orthosteric contribution 
(“the fast component”) but maintenance of the capacity to evoke activation via the allosteric site 
(“the slow component”) indicate an initial adoption of an orthosteric pose that is temporally 
extended in the hFFA2-ECL chimera (Figure 4J). Consistent with this, Ca2+-ionophore, A23187, but not 
C3 and 4-CMTB, elicited a calcium transient in hFFA2-R255A-ECL cells (Figure 4K). However, delayed 
activation via the allosteric site was still detectable for 4-CMTB as evidenced by robust accumulation 
of inositol phosphates (Figure 4L). These results led us to conclude that concomitant perturbation of 
the orthosteric binding pocket by Arg255Ala and of the gatekeeper function of ECL2 is well suited to 
illustrate the sequence of events during receptor activation by 4-CMTB, thereby associating the initial 
signaling impulse with an orthosteric and the prolonged signaling impulse with an allosteric 
mechanism.   
A single amino acid replacement restricts 4-CMTB to an orthosteric signaling mechanism 
The capacity to enhance duration of orthosteric 4-CMTB action in the ECL2 swap mutant prompted 
us to hypothesize that a similar effect might be achieved by replacement of key residues lining the 
allosteric FFA2 site by the corresponding FFA3 counterparts. Guided by homology modeling based on 
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the crystal structure of the related FFA1 receptor we replaced K652.60 by arginine (hFFA2-K65R), a 
residue which has not been probed previously as a determinant of 4-CMTB action (Figure 5A,B and 
32). Both C3 and 4-CMTB robustly activated hFFA2-K65R consistent with the mutated residue being 
outside the orthosteric area (Figure S5A-E). Most notably, however, and entirely consistent with our 
hypothesis, both C3 and 4-CMTB were now fully antagonized by CATPB (Figure 5C-E). Similar 
observations were made in IP accumulation assays: C3 and 4-CMTB-induced IP production was 
completely ablated by CATPB in a manner compatible with competitive antagonism for both ligands 
(Figure 5F-H, Table S4). Thus, at hFFA2-K65R the only mode of interaction available to 4-CMTB is 
occupancy of epitopes within the orthosteric pocket which manifests as complete sensitivity towards 
inhibition by CATPB.  
Structural analysis defines receptor engagement by 4-CMTB 
To further corroborate transient orthosteric first phase agonism of 4-CMTB, we examined its 
signaling pattern in mutant forms of hFFA2 designed to mimic the orthosteric site of FFA3: hFFA2-
S863.29G-Y903.33F-I1454.61Y-E166ECL2L. Because 4-CMTB is selective for FFA2 over FFA3, we predicted 
the quadruple mutant to specifically lose rapid orthosteric but preserve allosteric activation. C3, in 
contrast, should retain functionality in both assays because it is unable to discriminate between FFA2 
and FFA3. Indeed, C3 but not 4-CMTB induced intracellular Ca2+ flux (Figure 6C, left panel), however, 
both ligands produced substantial responses in IP accumulation assays (Figure 6C, right panel and 
Figure S6). In agreement with compromised orthosteric but functional allosteric signaling of the 
quadruple mutant, DMR recordings revealed rapid cell activation exclusively for C3 but delayed 
signaling that is superimposable for both ligands (Figure 6D). Based on these results, we predicted 
that combined substitution of a key orthosteric residue together with the allosteric Lys65Arg 
mutation should be sufficient to severely impair, if not ablate, 4-CMTB function. Indeed, complete 
lack of activation by 4-CMTB of hFFA2-K65R-R255A in DMR assays, despite appropriate surface 
expression, indicates experimental validation of our prediction (Figure 6E and Figure S6). Thus, we 
demonstrate that a single ligand may activate a GPCR in tandem via two topographically distinct 
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receptor sites (Figure S6), thereby introducing the novel pharmacological concept of sequentially 
activating ligands (SEALs).   
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Discussion 
Pharmacological targeting of more than one receptor site has to date only been achieved with 
dualsteric/bitopic ligands11,12. This ligand class consists of hybrid molecules, in which orthosteric and 
allosteric building blocks are bridged by a molecular linker. Thus, dualsteric/bitopic ligands span and 
simultaneously bind to orthosteric and allosteric receptor sites33. Dualsteric pharmacology is a 
captivating concept that underlies receptor subtype selectivity and may even confer signaling 
bias13,14. 4-CMTB also engages ortho- and allosteric sites, however, this small molecule is distinct 
from dualsteric/bitopic ligands in that it has minimal interaction with both sites simultaneously, and 
does not contain individual building blocks that are separated by a defined molecular linker. Rather it 
achieves stepwise activation of two spatially distinct FFA2 receptor sites by passing through one 
binding mode (site 1 interaction) before proceeding to another (site 2 interaction). These differences 
in orientation convey dynamics to agonism whose cellular consequences are seen only in real time. 
There is ample evidence that signal dynamics are a common means/principle of nature to encode 
cellular information and regulate cell physiology (Behar, Cell 2013; Yosef, Cell 2011; Purvis, Cell 2013) 
but knowledge about the mechanisms that GPCRs use to transceive temporal signaling codes is 
incomplete (and relatively few experimental tools are available to achieve temporal control over 
signaling waves) (Calebiro, PlosOne 2009; Ferrandon, NatChemBio 2009; Irannejad, Nature 2013). 
The here presented data describe the basic concept for a stepwise activation mode of a GPCR by a 
ligand that sequentially adopts multiple binding poses and thereby encodes receptor-mediated cell 
activation in a temporal dimension.  
A stepwise binding mode is not unprecedented in the literature, as several ligands are known to 
temporarily engage a disparate epitope before being routed to their terminal binding site. This has 
been shown for the orthosteric mAChR antagonists N-Methyl-scopolamine and Oxotremorine-M, 
which also bind to allosteric epitopes34. Molecular dynamics studies further proposed a temporary 
occupancy of an allosteric binding site by the orthosteric M2/3 mAChR antagonist Tiotropium35. 
Likewise, simulations with agonists and antagonists at β-adrenergic receptors propose an early 
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association with an unpredicted receptor site during the process of binding36. While all of these 
elegant studies underscore the importance of temporal aspects in ligand binding, none has linked 
receptor site occupancy with functional outcomes for each site. In fact, we speculate that GPCR 
ligands may frequently have a short-lived pause at an alternative site being guided to their final 
orientation. It is therefore conceivable that ligands classified as purely orthosteric or purely allosteric 
in fact halt en route of their binding pathway with potential functionality at distinct receptor sites. 
However, such a pharmacological phenotype may go unnoticed if compounds are exclusively 
analyzed in equilibrium assays. Thus it is likely that the concept discovered here for 4-CMTB does not 
merely reflect a new form of dynamic agonism of a single ligand but rather a more common 
phenomenon for both synthetic and even endogenous GPCR ligands. Indeed, two-step binding 
mechanisms are generally thought to occur when chemokines or large peptides bind their target 
receptors (Allen SJ et al., 2007 Annu rev Immunol; Castro M PNAS 2015). But even for small 
endogenous ligands of family A GPCRs such as acetylcholine multistep binding pathways have 
recently been suggested (Kappel 2015). Therefore, we speculate that our approach - if adapted to 
pharmacological analysis of other ligands - may affirm that sequential agonism, i.e. targeting more 
than one receptor site in a time-dependent manner, is more frequent than anticipated. 
An intriguing feature of orthosteric-allosteric targeting of FFA2 by 4-CMTB is the chronological order 
of these events. The structure of class A GPCRs would suggest that ligands initiate contact within the 
allosteric vestibule followed by passage into the transmembrane binding pocket to elicit an 
orthosteric response35,38. 4-CMTB, however, appears to navigate via a different route. We speculate 
that 4-CMTB achieves sequential orthosteric-allosteric targeting by entering via the lipid bilayer. Such 
an entry mode has previously been shown for several class A GPCR ligands39–44, particularly for those 
at lipid mediator GPCRs, such as the ago-allosteric agonist TAK875 (fasiglifam) at the related hFFA1 
receptor32. Clearly, further studies are needed to investigate the entry mode of 4-CMTB at FFA2 in 
more detail. Nevertheless and to the best of our knowledge, we here detect 4-CMTB to be the first 
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GPCR modulator for which sequential binding is associated with sequential activation via occupancy 
of two distinct receptor sites in tandem.  
Our multifaceted approach identifies 4-CMTB as a small molecule altering its activation mechanism 
over time. Although compelling experimental evidence is provided in favor of this unique mode of 
action, we chose to verify this novel concept with a kinetic model to rationalize the sequence of 
events on a molecular level (see Online Appendix). We propose that 4-CMTB initially binds the 
orthosteric receptor site (site 1) to then traverse to the thermodynamically more favorable allosteric 
site (site 2), whereby occupancy of site 2 subsequently results in negative allosteric modulation of 
the 4-CMTB effect at site 1. The apparent transient orthosteric signaling phase is therefore 
rationalized if 4-CMTB functioned as a NAM on its own efficacy at a distinct binding site. The 
extracellular loop 2 (ECL2) likely contributes to cessation of orthosteric signaling, since the ECL2-swap 
from the FFA2 receptor to the cognate counterpart of FFA3 substantially enhanced orthosteric 
elements of activation. Within hFFA2-K65R, however, which lacks a key residue of the allosteric 
pocket, 4-CMTB was essentially restricted to an orthosteric mechanism, as evidenced by the 
enhanced sensitivity toward the orthosteric FFA2 antagonist CATPB. In line with these findings, 
partial agonism of 4-CMTB progressively increased with a rank order of hFFA2-wt < hFFA2-ECL < 
hFFA2-K65R implying a correlation between residence and efficacy at the orthosteric site. Thus, 
capacity to switch 4-CMTB pharmacology to orthosteric in mutants lacking key allosteric residues and 
vice versa, i.e. to achieve both orthosteric and allosteric trapping, can only be rationalized by 
occupancy of two distinct sites by the same molecule, yet in a sequential manner. 
Significance: Drug recognition by GPCRs is a complex multistep process. Particularly for chemokines 
and large peptides two-site models are well established with ligands binding to site 1 before 
traversing to site 2 to induce a functional response. But also for marketed GPCR drugs time-
dependent adoption of different binding poses is thought to occur. Our study is significant because it 
expands this concept to small molecule ligands, and because it assigns functionality to individual sites 
adopted by the molecule along its binding pathway. We realize that considerable efforts are put into 
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the discovery and characterization of orthosteric, allosteric and dualsteric/bitopic ligands that allow 
to fine-tune cell responses and even achieve signaling bias. We also note that of the methods 
frequently applied to study activation mechanisms, most provide only snapshots of ligand activity. 
Given the growing body of evidence on drug binding pathways for GPCR ligands and recently also for 
endogenous transmitters - often revealed by elegant computational techniques - it may be advisable 
to allow real time to become a variable in functional assays thereby unveiling kinetic effects of drugs. 
Our study took advantage of two label-free biosensor platforms to monitor GPCR-mediated cell 
activation in real time and resulted in the discovery of a novel pharmacological principle to govern 
cell function in response to extracellular signals. We are certainly aware that label-free whole cell 
sensing does not uncover the fine molecular details on the receptor level as opposed to elegant 
FRET- or BRET-based methods which may resolve binding events in the millisecond to second range. 
Nevertheless, our study highlights the potential of this methodology to support identification of 
previously undiscovered binding sites that may only temporarily host GPCR ligands and to discover 
novel activation mechanisms in real time, in living cells, and in the absence of radioactive or 
fluorescent labels.  
 
Experimental Procedures 
Chemical compounds 
Propionic acid (C3) was purchased from Sigma-Aldrich. (S)-3-(2-(3-Chlorophenyl)acetamido)-4-(4-
(trifluoromethyl)phenyl)butanoic acid  (CATPB) and 2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-
yl)butanamide (4-CMTB) were synthesized as described previously in 31 and 19, respectively. The 
identity and purity (>99%) of CATPB and 4-CMTB were confirmed by NMR and HPLC. 
Plasmids and mutagenesis 
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Enhanced yellow fluorescent protein (eYFP) was C-terminally fused to FFA2 receptor cDNA and 
subcloned into pcDNA5/FRT/TO (Invitrogen) as previously reported30. Fluorescent microscopy images 
were obtained with cells either induced with 1 µg/mL doxycycline or transiently transfected with 
respective receptor mutant and subsequently visualized using a 20x objective (Leica DM IL LED Fluo, 
Leica Microsystems).  Site-directed mutagenesis in receptor cDNA in pcDNA5/FRT/TO was carried out 
following the QuikChange® protocol (Agilent Technologies). DpnI was used to digest template DNA 
and the mutated constructs were sequenced to confirm correct mutations. ECL2-swap mutant 
hFFA2-receptor (hFFA2-ECL) was generated as previously described 19.  
Cell culture and transfections 
To generate stable cell lines inducibly expressing the receptors, Flp-InTM T-RExTM 293 cells (Invitrogen) 
were cotransfected with pcDNA5/FRT/TO containing the receptor of interest and pOG44 (Invitrogen) 
in a ratio of 1:9 using a calcium phosphate DNA precipitation method according to manufacturer’s 
instructions. pOG44 drives expression of recombinase, which enables recombination of FRT sites in 
the receptor-cDNA carrying plasmid and the host genome of Flp-InTM T-RExTM 293 cells. In 
consequence, Hygromycin B resistance introduced by pcDNA5/FRT/TO can identify receptor-
transfected cells. Stably transfected Flp-InTM T-RExTM 293 cells were cultured in Dulbecco’s modified 
Eagle‘s medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), 
streptomycin (100 µg/mL), Hygromycin B (100 µg/mL) and Blasticidin (15 µg/mL) at 37°C and 5% CO2. 
Untransfected Flp-InTM T-RExTM 293 host cells were maintained in DMEM supplemented with 10% 
(v/v) FBS, penicillin (100 U/mL), streptomycin (100 µg/mL), 100 µg/mL Zeocin and 15 µg/mL 
Blasticidin at 37°C and 5% CO2. All experiments were carried out after inducing receptor expression 
with 1 µg/mL doxycycline for approximately 18 hours. 
Dynamic mass redistribution (DMR) assay 
DMR measurements were performed using either the Epic® System (Corning) or the EnSpire® System 
(PerkinElmer) as previously described in detail28,29. Briefly, 20,000 cells per well were seeded into a 
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384 well biosensor plate in culture medium and left to adhere for 4 – 6 hours at 37°C and 5% CO2. 
Subsequently, medium was replaced by doxycycline (1 µg/mL) containing culture medium and the 
plate was incubated at 37°C and 5% CO2 for approximately 18 hours to drive receptor expression. 
Cells were then washed at least twice with HBSS (supplemented with 20mM HEPES) and incubated 
for 1 hour at 37°C on the DMR reader. Compounds were diluted in HBSS (+20 mM HEPES) and added 
to the biosensor plate after 3 minutes of baseline read with a liquid handling system (CyBi®-SELMA, 
CyBio). Immediately after compound addition, DMR response was recorded for at least 1.5 hours. 
Where necessary, cells were preincubated with antagonist for 30 minutes. 
Bioimpedance assay 
Bioimpedance measurements were performed using the CellKeyTM System (MolecularDevices). For 
this purpose, 15,000 cells were seeded into 384 well poly-D-lysine (PDL)-coated CellKeyTM system 
microplates in culture medium and centrifuged at 150 x g for 1 minute. The plate was then incubated 
for 4 – 6 hours at 37°C and 5% CO2 to allow cells to adhere to the biosensor plate. Thereafter, 
medium was replaced by doxycycline containing (1 µg/mL) culture medium and incubated for 
approximately 18 hours at 37°C and 5% CO2. Cells were then washed with HBSS (supplemented with 
20 mM HEPES and the appropriate amount of DMSO according to the compound dilutions) three 
times using a manifold, which leaves 5 µL left in each well. 15 µL of wash buffer was added and the 
plate was subsequently transferred to the impedance reader and incubated for 1 hour at 37°C. 
Compounds were diluted in HBSS (containing 20 mM HEPES) and DMSO amount was adjusted in all 
dilution steps. 25 µL of compound solution was dispensed into a 384 well compound plate and 
subsequently incubated in the CellKeyTM system. A baseline read was then recorded for 5 minutes 
and compound solutions were added directly onto the biosensor plate. Changes in cellular 
impedance (ohms) were measured as a result of extracellular current (dZiec) for 1 hour. If needed, 
cells were preincubated with antagonist for 30 minutes. 
Calcium flux assay 
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Intracellular calcium mobilization was measured using the FLIPR® Calcium 5 Assay Kit in conjunction 
with the FlexStation® 3 Multimode Benchtop Reader (Molecular Devices). Briefly, cells were seeded 
into poly-D-lysine coated 96 well microplates at a density of 60,000 cells per well. After 4 – 6 hours 
the medium was replaced by culture medium supplemented with 1 µg/mL doxycycline and incubated 
for 18 hours at 37°C and 5% CO2. Thereafter, cells were loaded with the FLIPR® Calcium 5 dye for 30 
minutes at 37°C and subsequently processed according to manufacturer’s instructions. Where 
necessary, cells were preincubated with antagonist for 30 minutes. 
IP and cAMP assay 
Intracellular levels of the second messenger IP and cAMP were quantified with a Mithras LB 940 
multimode reader (Berthold Technologies) using the HTRF®-IP-One kit and the HTRF®-cAMP dynamic 
kit (CisBio International), respectively, according to the manufacturer’s instructions. Briefly, for the IP 
assay, 10,000 receptor-expressing cells were seeded into a 384 well microplate and incubated for 20 
minutes at 37°C. Cells were then stimulated with agonist for 30 minutes and IP levels were quantified 
using the HTRF®-IP1 kit. For the cAMP assay, 3,000 cells were seeded into a 384 well microplate and 
incubated for 20 minutes at 37°C. Cells were stimulated with a mixture of agonist and forskolin for 30 
minutes and intracellular levels of cAMP were subsequently analyzed using the HTRF®-cAMP dynamic 
kit. If needed, cells were preincubated with antagonist for 30 minutes. 
pERK1/2 assay 
Intracellular levels of phosphorylated ERK1/2 were quantified using the HTRF®-Cellul’erk kit (Cisbio 
International) and the Mithras LB 940 multimode reader (Berthold Technologies) following 
manufacturer’s instructions. Briefly, 80,000 cells were seeded onto poly-D-lysine coated 96 well 
microplates and incubated for 4 – 6 hours at 37°C. Receptor expression was initiated by adding 
doxycycline (final concentration 1 µg/mL) and the plate was incubated for 18 hours at 37°C and 5% 
CO2. Thereafter medium was replaced by starvation medium, lacking 10% FCS, and incubated for 
another 4 hours at 37°C and 5% CO2. Compounds were added and pERK1/2 levels were determined 
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using the HTRF®-Cellul’erk kit at time points as indicated. Where necessary, cells were preincubated 
with antagonist for 30 minutes. 
Molecular modeling and Molecular Dynamics Studies 
The FFA1 crystal structure with PDB code 4PHU32 was used as a template to generate the FFA2 
homology model employing the Prime 3.0 program (Schrödinger, LLC, USA) with the default settings. 
The model was refined using a default energy minimization protocol implemented in Prime 3.0. 
Docking was conducted using Glide 6.5 (Schrödinger, LLC, USA) with the receptor grid defined by 
residues at positions 3.37, 4.57, 5.39, 6.51 and 7.53.  The standard precision scoring function was 
used for docking. Modelling figures were generated with Maestro 9.9 (Schrödinger, LLC, USA). 
Molecular surface was built with probe radius of 0.9 Å. 
Curve fitting and data analysis 
All calculations were carried out using GraphPad Prism® 5.04 software (GraphPad Software). All 
label-free data from the DMR and bioimpedance assay were buffer-corrected and quantified as 
indicated. Calcium response was calculated using the maximal peak fluorescence within 80 seconds. 
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Figure legends 
Figure 1. Label-free biosensors disclose kinetic differences between C3 and 4-CMTB 
(A-D) Label-free real-time traces of HEK293 cells stably transfected with the hFFA2-wt receptor 
stimulated with C3 (A,C) and 4-CMTB (B,D) recorded with the impedance- and optical-based 
biosensor, respectively. (E-H) Concentration-response-curves (CRC) of FFA2 agonists calculated at 
early (E,F) and late (G,H) time points from bioimpedance (negative peak within 0 – 600 sec (E) and at 
3,600 sec (G)) and DMR recordings (peak within 0 – 800 sec (F) and at 6,000 sec (H)). (I,J) Real-time 
signatures of 4-CMTB at the hFFA2-R255A construct in the impedance (I) and the DMR assay (J), 
respectively. (K,L) CRC of 4-CMTB at the hFFA2-R255A receptor calculated from early or late cell 
responses in the impedance (K) and DMR assay (L), respectively. Label-free signatures are shown as 
representative traces (mean + SEM), measured in triplicates. CRC are depicted as mean values ± SEM 
from three to six independent experiments. See also Figure S1 and Table S1. 
Figure 2. CATPB is an orthosteric antagonist at the hFFA2-wt receptor 
(A) Chemical structure of CATPB. (B,C) Effect of increasing concentration of CATPB on DMR-derived 
CRC of C3 at the hFFA2-wt receptor (B) with corresponding Schild plot (C). (D,E) Lack of effect of 
CATPB on 4-CMTB (30 µM) signaling at the hFFA2-R255A receptor in the DMR (D) and bioimpedance 
(E) assay. (F) Analysis of DMR data from panel (D) at different time points (500 sec vs. 6,000 sec.). 
Real-time recordings are shown as representative traces (mean + SEM), measured in triplicates. 
Quantified data are shown as mean values ± SEM of three to six independent experiments. Where 
not shown error bars lie within dimensions of the symbols. See also Figure S2. 
Figure 3. 4-CMTB shows time-dependent sensitivity towards the orthosteric antagonist CATPB and 
a mutation of a key residue within the orthosteric site. 
(A,B) Effect of CATPB on 30 µM C3 (A) and 4-CMTB (B)-mediated hFFA2-wt receptor activation in the 
optical-based label-free readout. (C,D) Effect of CATPB on hFFA2-wt Ca2+ flux evoked by varying 
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concentrations of C3 (C) and 4-CMTB (D). (E) Analysis of IC50-shifts according to Cheng-Prusoff (slope: 
C3: 1.040 ± 0.024, r2: 0.9946; 4-CMTB: 1.011 ± 0.045, r2: 0.9805). (F) CATPB effect on C3 (pIC50: 6.22 ± 
0.39) or 4-CMTB-induced IP accumulation at the hFFA2-wt receptor. Data were baseline-corrected to 
remove the contribution of constitutive activity to IP signaling and CATPB responsiveness. (G) Impact 
of CATPB on C3 or 4-CMTB-mediated inhibition of 0.3 µM forskolin-induced cAMP production. (H) 
Time point-differentiated analysis of CATPB effect on 4-CMTB-mediated ERK1/2 phosphorylation. (I) 
Ca2+ flux in hFFA2-R255A expressing HEK293 cells upon stimulation with FFA2 agonists. Calcium-
ionophore A23187 is shown as control. (J-L) Equilibrium CRC of C3 and 4-CMTB at the hFFA2-R255A 
receptor in the IP- (pEC50: 4.70 ± 0.09) (J), the cAMP-(pEC50: 5.96 ± 0.22) (K) and the pERK1/2-assay 
(pEC50: 5.15 ± 0.04) (L). Label-free signatures are shown as representative traces + SEM, measured in 
triplicates. Bar diagrams and CRC represent mean values ± SEM of at least three independent 
experiments. Statistical significance was analyzed by two-tailed, unpaired Student’s t test: *p < 0.05, 
**p < 0.01, ***p < 0.001. See also Figure S3 and Table S2. 
Figure 4. Structural changes within the extracellular receptor region intensify susceptibility of 
4-CMTB effect to interrogation at the orthosteric site level 
 (A,B) Effect of increasing concentrations of CATPB on DMR traces of 30 µM C3 (A) and 4-CMTB (B) 
activating the hFFA2-ECL receptor. (C,D) Comparison of CATPB inhibition at early time points (800 
sec) on hFFA2-ECL activation by C3 (C) or 4-CMTB (D). (E,F) Comparison of CATPB inhibition at early 
time points (800 sec) on hFFA2-wt activation by C3 (E) or 4-CMTB (F). (G,H) Analysis of IC50-shifts 
according to Cheng-Prusoff at the hFFA2-ECL (slope: C3: 0.992 ± 0.020, r2: 0.996; 4-CMTB: 0.976 ± 
0.046, r2: 0.978) (G) and hFFA2-wt receptor (slope: C3: 1.049 ± 0.010, r2: 0.999; 4-CMTB: 1.030 ± 
0.029, r2: 0.992) (H). (I) Temporal quantification of CATPB-sensitivity at the hFFA2-wt and the hFFA2-
ECL receptor for 30 µM 4-CMTB. (J) 4-CMTB effect at the double mutant hFFA2-R255A-ECL in the 
DMR assay, Forskolin (fsk) is shown as control. (K) Ca2+ flux of FFA2 agonists at the hFFA2-R255A-ECL 
receptor, calcium-ionophore A23187 is shown as control. (L) Assessment of IP levels upon hFFA2-
R255A-ECL receptor stimulation with C3 or 4-CMTB (pEC50: 4.23 ± 0.03) under equilibrium conditions. 
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Representative real-time traces are shown as mean + SEM, measured in triplicates. Quantified data 
are depicted as mean values ± SEM of at least three independent experiments. See also Figure S4 and 
Table S3. 
Figure 5. Identification of K652.60 as a key residue within the allosteric site that controls trapping of 
4-CMTB in an orthosteric pose. 
(A,B) Superimposition of FFA2 homology models. K65 is pointed towards the binding cavity in the 
FFA1-based model (white) due to the proline kink at position 2.58 that unwinds helix 2. This proline 
kink is conserved in the free fatty acid receptor family but absent in the previously used β2-
adrenergic receptor-based model45 (cyan). (C,D) Effect of increasing concentrations of CATPB on DMR 
signatures of 30 µM C3 (C) and 4-CMTB (D) activating the hFFA2-K65R receptor. (E) CATPB inhibition 
of hFFA2-K65R receptor-mediated cell activation by C3 (pIC50: 6.82 ± 0.06) or 4-CMTB (pIC50: 6.97 ± 
0.10). (F,G) CATPB inhibition of C3 (F) or 4-CMTB (G)-elevated IP levels. (H) Analysis of IC50-shifts 
according to Cheng-Prusoff (slope: C3: 1.007 ± 0.029, r2: 0.990; 4-CMTB: 1.033 ± 0.050, r2: 0.972). 
Representative real-time traces are shown as mean + SEM, measured in triplicates. Quantified data 
are depicted as mean values ± SEM of three independent experiments. See also Figure S5 and Table 
S4. 
Figure 6.  
 (C) Ca2+-flux and IP response after activation with C3 or 4-CMTB at the FFA2 quadruple mutant. (D) 
DMR traces to C3 and 4-CMTB stimulation of the FFA2 quadruple mutant transfected HEK293 cells. 
(E) DMR readout of HEK293 cells transiently expressing the hFFA2-K65R-R255A receptor mutant. 
Carbachol (Cch) is shown as control. Representative real-time traces are shown as mean values, 
measured in triplicates. Quantified data are depicted as mean values ± SEM of three independent 
experiments. See also Figure S6. 
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